Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2021 1
2022 11
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
D'Alessio A, Fulgenzi CAM, Pinato DJ. D'Alessio A, et al. Among authors: fulgenzi cam. Hepatology. 2022 Oct;76(4):E86. doi: 10.1002/hep.32587. Epub 2022 Jun 22. Hepatology. 2022. PMID: 35603477 No abstract available.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Among authors: fulgenzi cam. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Fulgenzi CAM, et al. Eur J Cancer. 2022 Nov;175:204-213. doi: 10.1016/j.ejca.2022.08.024. Epub 2022 Sep 20. Eur J Cancer. 2022. PMID: 36148739 Free article.
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. Xie E, et al. Among authors: fulgenzi cam. JAMA Oncol. 2023 Oct 1;9(10):1423-1431. doi: 10.1001/jamaoncol.2023.3284. JAMA Oncol. 2023. PMID: 37615958 Free PMC article.
Reply.
D'Alessio A, Fulgenzi CAM, Pinato DJ. D'Alessio A, et al. Among authors: fulgenzi cam. Hepatology. 2022 Oct;76(4):E82-E83. doi: 10.1002/hep.32553. Epub 2022 Jul 12. Hepatology. 2022. PMID: 35503722 No abstract available.
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.
Manfredi GF, Celsa C, John C, Jones C, Acuti N, Scheiner B, Fulgenzi CAM, Korolewicz J, Pinter M, Gennari A, Mauri FA, Pirisi M, Minisini R, Vincenzi F, Burlone M, Rigamonti C, Donadon M, Cabibbo G, D'Alessio A, Pinato DJ. Manfredi GF, et al. Among authors: fulgenzi cam. J Hepatocell Carcinoma. 2023 Nov 3;10:1955-1971. doi: 10.2147/JHC.S291553. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 37941812 Free PMC article. Review.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Vithayathil M, et al. Among authors: fulgenzi cam. Hepatol Int. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1. Hepatol Int. 2023. PMID: 37005953 Free PMC article.
Prognostic and predictive factors in pancreatic cancer.
Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Dell'Aquila E, et al. Among authors: fulgenzi cam. Oncotarget. 2020 Mar 10;11(10):924-941. doi: 10.18632/oncotarget.27518. eCollection 2020 Mar 10. Oncotarget. 2020. PMID: 32206189 Free PMC article. Review.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. Balcar L, et al. Among authors: fulgenzi cam. JHEP Rep. 2023 Dec 12;6(2):100982. doi: 10.1016/j.jhepr.2023.100982. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274490 Free PMC article.
23 results